Skip to content
Medical Health Aged Care

biomodal Launches Certified Service Provider Program for Duet Multiomics 5-Base and 6-Base Sequencing Solutions

biomodal 3 mins read
CAMBRIDGE, England--BUSINESS WIRE--

biomodal, an omics-based life sciences technology and analytics company, today announced it has launched a Certified Service Provider (CSP) program with partners around the globe to meet the increasing demand for its novel duet multiomics solutions. The organizations are partnering with biomodal as they work to deliver transformative data and insights for researchers in areas such as disease detection and therapy selection and monitoring, as well as providing mechanistic insights into disease.

biomodal’s CSP program is a worldwide network of validated service organizations utilizing the company’s duet multiomics sequencing technology, including duet evoC and duet +modC. biomodal CSPs undergo standardized training and certification to ensure they deliver the highest-quality data to their clients.

Highlighted service providers include:

“This technology offers a more complete picture of the biology and gene regulation in cancer, ageing and cardiovascular health, and can even unlock an understanding of the effects of climate change on species development,” said Dr.Orion Tong, R&D Lead at Garvan Genomics Platform.

“Our partnership with biomodal puts cutting-edge multiomic tools directly into the hands of scientists,” said Dr. Keith Booher, Services Director at Zymo Research Corporation. “The ability to profile 5mC, 5hmC, and the four canonical bases in one workflow is a transformative step for understanding disease biology, and it’s changing the game.”

Dr. Per Hoffmann, CCO at Life and Brain GmbH, “With biomodal’s duet multiomics solutions, we deliver transformative insights by generating and analyzing the 5-base and 6-base genome. This partnership enables us to continuously provide innovative services that deepen understanding of normal and disease biology and enable better identification of disease-relevant biomarkers.”

“As early adopters of the 5-base and 6-base solutions from biomodal, we are excited to share that we are now officially a Certified Service Provider,” said Ioannis Ragoussis, Head of Genome Sciences at McGill Genome Center. “This milestone enables us to support more advanced research and deliver greater depth of mechanistic understanding to the researchers we serve.”

“We continually evaluate the most advanced technologies for our research community. biomodal’s 6-base solution opens new frontiers in genetics and epigenetics, revealing insights that were previously out of reach,” said Claudia Lalancette, Director of the University of Michigan Epigenomics Core Lab.

“We are excited to extend the novel benefits of our duet multiomics solutions by partnering with leaders in the life sciences community to better support our customers worldwide,” said Peter Fromen, CEO of biomodal. “Our bCSP program provides a competitive advantage to service providers and helps ensure that their own customers receive the highest quality multiomic data using biomodal technology.”

Interested in learning more about biomodal’s CSP program, visit: https://biomodal.com/certified-service-providers/

About biomodal ltd.

biomodal is an omics-based life sciences technology and analytics company delivering products that bring the dynamism of our ever-changing biology into focus. Our duet multiomics solutions enable more epigenetic information from a single, low input DNA sample without complex, resource intensive bioinformatics, or harsh chemical treatment. Our single-base-resolution, resolved sequencing approach unlocks the combinatorial power of genetic and epigenetic information in one workflow, elucidating greater biological insight within the fields of cancer, neurodegenerative disease, and ageing.


Contact details:

Media contact:

Donna McDade-Walker, PhD
VP, Global Marketing & Product Management
[email protected]

Media

More from this category

  • Medical Health Aged Care
  • 12/12/2025
  • 10:11
Cosette Pharmaceuticals, Inc.

Termination of Proposed Acquisition of Mayne Pharma

BRIDGEWATER, N.J.–BUSINESS WIRE– Cosette Pharmaceuticals, Inc. (Cosette), a U.S.-based, fully integrated pharmaceutical company, confirms that on 9 December 2025 it served a notice on…

  • Contains:
  • Medical Health Aged Care
  • 12/12/2025
  • 08:55
Royal Australian College of GPs

Universal Health Coverage Day: RACGP calls out need for better funding for chronic conditions and preventive care

Specialist GPs have marked International Universal Health Coverage (UHC) Day by joining the World Health Organization in highlighting the devastating impact of health costs. The Royal Australian College of GPs (RACGP) has stressed that a public health system which forces patients with complex or chronic conditions to pay out of pocket for longer consultations can’t claim to offer universal coverage, and urged governments to protect patients from financial hardship. “Health is a human right,” RACGP President Dr Michael Wright said. “Australia recognises the right of everyone to the highest attainable standard of physical and mental health, and our governments are…

  • Contains:
  • Medical Health Aged Care, Women
  • 12/12/2025
  • 01:00
Breast Cancer Trials

Simple blood tests could help tailor treatment for aggressive breast cancer

Key Facts: Blood tests detecting circulating tumour DNA could help guide treatment for triple negative breast cancer patients Absence of tumour DNA in blood…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.